News

GSK to buy efimosfermin for up to $2 billion
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...
BioSpace1d
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...
Targeted Oncology1h
Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC
Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...
GSK, partner iTeos scrap development of lung cancer therapy
Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...
FTSE 100 Live 14 May: GSK unveils $2bn acquisition, Imperial Brands posts results
Under the agreement to acquire Boston Pharmaceuticals' lead asset Efimosfermin, GSK will pay $1.2 billion upfront followed by ...
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 ...
Explore more
Fierce Biotech2d
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...
GSK slips Tuesday, underperforms market
GSK PLC closed 25.53% below its 52-week high of £18.24, which the company reached on May 16th.